The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE−/−) mice-Reference-Cited by-同舟云学术

The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE−/−) mice

Published:2009-07 Issue:1 Volume:205 Page:55-62
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Ivanovski Ognen,Nikolov Igor G.,Joki Nobuhiko,Caudrillier Axelle,Phan Olivier,Mentaverri Romuald,Maizel Julien,Hamada Yasuhiro,Nguyen-Khoa Thao,Fukagawa Masafumi,Kamel Said,Lacour Bernard,Drüeke Tilman B.,Massy Ziad A.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference36 articles.

1. Coronary artery disease as a definitive risk factor of short-term outcome after starting hemodialysis in diabetic renal failure patients;Joki;Clin Nephrol,2001

2. Atherosclerosis and arteriosclerosis in chronic renal failure;London;Kidney Int,1997

3. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality;London;Nephrol Dial Transplant,2003

4. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?;Raggi;J Am Coll Cardiol,2002

5. Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease?;Kennedy;Am J Med,2001

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term therapy with R568 ameliorated secondary hyperparathyroidism but does not prevent aortic valve calcification in uremic rats;Frontiers in Nephrology;2024-08-06

2. Similarities and Differences of Vascular Calcification in Diabetes and Chronic Kidney Disease;Diabetes, Metabolic Syndrome and Obesity;2024-01

3. Multicentre, open-label, randomised, controlled trial to compare early intervention with calcimimetics and conventional therapy in preventing coronary artery calcification in patients with secondary hyperparathyroidism (UPCOMING): a study protocol;BMJ Open;2024-01

4. Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case–control study;Frontiers in Pharmacology;2023-10-10

5. Non‐Additive Effects of Combined NOX1 /4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder ( CKD‐MBD );JBMR Plus;2022-02-11